Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

Fintel reports that on June 11, 2025, Raymond James initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Strong ...

A new agreement between the FDA and Avidity Biosciences could further assuage industry concerns about the agency’s stance on ...

SOURCE Avidity Biosciences, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.42, along with a high estimate of $75.00 and a low estimate of $54.00. Surpassing the ...

Avidity Biosciences, Inc. (RNA) shares soared 11.3% in the last trading session to close at $29.77. The move was backed by solid volume with far more shares changing hands than in a normal session.

SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

SOURCE Avidity Biosciences, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered ...